Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine

References

• Schede HH, Schneider CG, Stergiadou J, et al. Spatial tissue profiling by imaging-free molecular tomography. bioRxiv. 2020.DOI: https://doi.org/10.1101/2020.08.04.235655 BIORxiv
   Google Scholar
• Bassiouni R, Gibbs LD, Craig DW, et al. Applicability of spatial transcriptional profiling to cancer research. Mol Cell. 2021;81(8):1631–1639.
   PubMed Web of Science ®Google Scholar
• Asp M, Bergenstråhle J, Lundeberg J. Spatially resolved transcriptomes—Next generation tools for tissue exploration. BioEssays. 2020;42(10):1900221.
   Web of Science ®Google Scholar
• Herrera JA, Mallikarjun V, Rosini S, et al. Laser capture microdissection coupled mass spectrometry (LCM-MS) for spatially resolved analysis of formalin-fixed and stained human lung tissues. Clin Proteomics. 2020;17(1):24.
   PubMed Web of Science ®Google Scholar
• Nichterwitz S, Benitez JA, Hoogstraaten R, et al. LCM-Seq: a method for spatial transcriptomic profiling using laser capture microdissection coupled with PolyA-Based RNA sequencing.In: Gaspar I, editor. RNA Detect [Internet]. New York: Springer New York; 2018 [cited 2021 Jun 14]. p. 95–110. Available from:
   Google Scholar
• Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser Capture Microdissection. Science. 1996;274(5289):998–1001.
   PubMed Web of Science ®Google Scholar
• Pin E, Stratton S, Belluco C, et al. A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. Mol Oncol. 2016;10(10):1585–1594.
   PubMed Web of Science ®Google Scholar
• Chiechi A, Novello C, Magagnoli G, et al. Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both Carcinoma and sarcoma primary tumors. Clin Cancer Res. 2013;19(9):2473–2485.
   PubMed Web of Science ®Google Scholar
• Einspahr JG, Calvert V, Alberts DS, et al. Functional protein pathway activation mapping of the progression of normal skin to squamous cell Carcinoma. Cancer Prev Res (Phila). 2012;5(3):403–413.
   PubMed Web of Science ®Google Scholar
• Munsamy T, Bouwer G. Determination of the virulence of single nucleopolyhedrovirus occlusion bodies using a novel laser capture microdissection method. J Gen Virol. 2020;101(12):1300–1304.
   PubMed Web of Science ®Google Scholar
• George P, Sharma A, Sharakhov IV. 2D and 3D chromosome painting in malaria mosquitoes. J Vis Exp. 2014;83:51173. DOI: https://doi.org/10.3791/51173
   Google Scholar
• Iyer EPR, Cox DN. Laser Capture Microdissection of drosophila peripheral neurons. J Vis Exp. 2010;39:2016. DOI: https://doi.org/10.3791/2016
   Google Scholar
• Ando A, Kirkbride RC, Jones DC, et al. LCM and RNA-seq analyses revealed roles of cell cycle and translational regulation and homoeolog expression bias in cotton fiber cell initiation. BMC Genomics. 2021;22(1):309.
   PubMed Web of Science ®Google Scholar
• Gautam V, Chatterjee S, Sarkar AK. Single cell type specific RNA isolation and gene expression analysis in rice using Laser Capture Microdissection (LCM)-Based method. In Bandyopadhyay A, Thilmony R, editors. Rice Genome Eng Gene Ed [Internet]. New York (NY): Springer US; 2021 [cited 2021 Aug 3]. p. 275–283. Available from:
   Google Scholar
• Santegoeds RGC, Yakkioui Y, Jahanshahi A, et al. Notochord isolation using laser capture microdissection. J Chem Neuroanat. 2017;80:37–43.
   PubMed Web of Science ®Google Scholar
• Greene RM, Smolenkova I, Pisano M. Laser capture microdissection of Murine Embryonic neural crest cells. In: Schwarz Q, Wiszniak S, editors. Neural crest cells [Internet]. New York: Springer New York; 2019 [cited 2021 Jun 14]. p. 121–133. Available from:
   Google Scholar
• Cefalo CMA, Mezza T, Giaccari A, et al. A systematic comparison of protocols for recovery of high-quality RNA from human islets extracted by Laser Capture Microdissection. Biomolecules. 2021;11(5):625.
   PubMed Web of Science ®Google Scholar
• Nyalwidhe JO, Grzesik WJ, Burch TC, et al. Comparative quantitative proteomic analysis of disease stratified laser captured microdissected human islets identifies proteins and pathways potentially related to type 1 diabetes. PLOS ONE. 2017;12(9):e0183908. In Pietropaolo M, editor.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lanzoni G, Battarra M, et al. Label-Free LC-MS/MS strategy for comprehensive proteomic profiling of human islets collected using laser capture microdissection from frozen pancreata.In: Wang X, Kuruc M, editors. Funct Proteomics [Internet]. New York: Springer New York; 2019 [cited 2021 Jun 14]. p. 253–264. Available from:
   Google Scholar
• Mollee P, Boros S, Loo D, et al. Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Clin Proteomics. 2016;13(1):30.
   PubMedGoogle Scholar
• Datta S, Malhotra L, Dickerson R, et al. Laser capture microdissection: big data from small samples. Histol Histopathol. 2015;30:1255–1269.
   PubMed Web of Science ®Google Scholar
• Macdonald JA, Murugesan N, Pachter JS. Endothelial cell heterogeneity of blood-brain barrier gene expression along the cerebral microvasculature. J Neurosci Res. 2009;NA–NA. DOI: https://doi.org/10.1002/jnr.22316
   Google Scholar
• Song HW, Foreman KL, Gastfriend BD, et al. Transcriptomic comparison of human and mouse brain microvessels. Sci Rep. 2020;10(1):12358.
   PubMed Web of Science ®Google Scholar
• Hudock TA, Kaushal D. A novel microdissection approach to recovering mycobacterium tuberculosis specific transcripts from formalin fixed paraffin embedded lung granulomas. J Vis Exp. 2014;88:51693. DOI: https://doi.org/10.3791/51693.
   Google Scholar
• Zimmerman M, Blanc L, Chen P-Y, et al. Spatial quantification of drugs in pulmonary tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry (LCM-LC/MS). J Vis Exp. 2018;88:57402. DOI: https://doi.org/10.3791/51693
   Google Scholar
• Yang X, Song Y, Liang T, et al. Application of laser capture microdissection and PCR sequencing in the diagnosis of Coccidioides spp. infection: a case report and literature review in China. Emerg Microbes Infect. 2021;10(1):331–341.
   PubMed Web of Science ®Google Scholar
• Chae YK, Gagliato D de M, Pai SG, et al. The Association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer. PloS One. 2016;11(4):e0152585.
   PubMed Web of Science ®Google Scholar
• Espina V, Edmiston KH, Heiby M, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics MCP. 2008;7(10):1998–2018.
   PubMed Web of Science ®Google Scholar
• Mnatsakanyan R, Shema G, Basik M, et al. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry. Expert Rev Proteomics. 2018;15(6):515–535.
   PubMed Web of Science ®Google Scholar
• Hunt AL, Bateman NW, Barakat W, Extensive intratumor proteogenomic heterogeneity revealed by multiregion sampling in high-grade serous Ovarian tumor specimens. bioRxiv. 2021;24(7):102757. DOI: https://doi.org/10.1016/j.isci.2021.102757.eCollection 2021 Jul 23.
   Google Scholar
• Wulfkuhle JD, Yau C, Wolf DM, et al. Evaluation of the HER/PI3K/AKT Family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with neratinib in the I-SPY 2 TRIAL. JCO Precis Oncol. 2018 Aug 16;2:PO.18.00024. doi:https://doi.org/10.1200/PO.18.00024. eCollection 2018. Online only.
   Google Scholar
• Wulfkuhle JD, Yau C, Wolf DM, et al. Abstract P3-07-48: prediction of complete pathologic response to veliparib/carboplatin plus standard neoadjuvant therapy in HER2 negative breast cancer: exploratory protein pathway marker results from the I-SPY 2 trial. Cancer Res. 2016;76: P3-P3-07–48.
   Web of Science ®Google Scholar
• Wolf DM, Yau C, Wulfkuhle J, et al. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. Npj Breast Cancer. 2020;6(1):1–8.
   PubMed Web of Science ®Google Scholar
• Pierobon M, Ramos C, Wong S, et al. Enrichment of PI3K-AKT–mTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(16):4919–4928.
   PubMed Web of Science ®Google Scholar
• I-SPY 2 TRIAL Investigators, Wolf DM, Yau C, Wulfkuhle J, et al. Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. Npj Breast Cancer. 2020;6(1):48.
   PubMed Web of Science ®Google Scholar
• Cheng PF, Dummer R, Levesque MP. Data mining The Cancer Genome Atlas in the era of precision cancer medicine. Swiss Med Wkly. 2015;145:w14183.
   PubMed Web of Science ®Google Scholar
• Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97–100.
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Bichsel VE, Calvert VS, et al. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(15):3614–3621.
   PubMed Web of Science ®Google Scholar
• Casasent AK, Schalck A, Gao R, et al. Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell. 2018;172(1–2):205–217.e12.
   PubMed Web of Science ®Google Scholar
• Bonner RF. CELL SAMPLING: Laser Capture Microdissection: molecular analysis of tissue. Science. 1997;278(5342):1481–1483.
   PubMed Web of Science ®Google Scholar
• Simone NL, Bonner RF, Gillespie JW, et al. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet. 1998;14(7):272–276.
   PubMed Web of Science ®Google Scholar
• Gallagher RI, Blakely SR, Liotta LA, et al. Laser Capture Microdissection: arcturusxt infrared capture and UV cutting methods.In: Espina V, Liotta LA, editors. Mol profiling [Internet]. Totowa (NJ): Humana Press; 2012 [cited 2021 Jun 14]. p. 157–178. Available from:
   Google Scholar
• Nichterwitz S, Chen G, Aguila Benitez J, et al. Laser capture microscopy coupled with Smart-seq2 for precise spatial transcriptomic profiling. Nat Commun. 2016;7(1):12139.
   PubMedGoogle Scholar
• Amrhein L, Fuchs C. stochprofML: stochastic profiling using maximum likelihood estimation in R. BMC Bioinformatics. 2021;22(1):123.
   PubMed Web of Science ®Google Scholar
• Andersson A, Bergenstråhle J, Asp M, et al. Single-cell and spatial transcriptomics enables probabilistic inference of cell type topography. Commun Biol. 2020;3(1):565.
   PubMed Web of Science ®Google Scholar
• Brasko C, Smith K, Molnar C, et al. Intelligent image-based in situ single-cell isolation. Nat Commun. 2018;9(1):226.
   PubMedGoogle Scholar
• Angelidis I, Simon LM, Fernandez IE, et al. An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat Commun. 2019;10(1):963.
   PubMedGoogle Scholar
• Hipp J, Johann D, Chen Y, et al. Computer-aided laser dissection: a microdissection workflow leveraging image analysis tools. J Pathol Inform. 2018;9(1):45.
   PubMedGoogle Scholar
• Huang P, Kong Q, Gao W, et al. Spatial proteome profiling by immunohistochemistry-based laser capture microdissection and data-independent acquisition proteomics. Anal Chim Acta. 2020;1127:140–148.
   PubMed Web of Science ®Google Scholar
• Großerueschkamp F, Gerwert K. Label-free digital pathology by infrared imaging. Biomed Spectrosc Imaging. 2020;9(1–2):5–12.
   Web of Science ®Google Scholar
• Schnell M, Mittal S, Falahkheirkhah K, et al. All-digital histopathology by infrared-optical hybrid microscopy. Proc Natl Acad Sci. 2020;117(7):3388–3396.
   PubMed Web of Science ®Google Scholar
• Wang N, Wang R, Zhang X, et al. Spatially-resolved proteomics and transcriptomics: an emerging digital spatial profiling approach for tumor microenvironment. Vis Cancer Med. 2021;2:1.
   Google Scholar
• Toki MI, Merritt CR, Wong PF, et al. High-Plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(18):5503–5512.
   PubMed Web of Science ®Google Scholar
• Lamanna J, Scott EY, Edwards HS, et al. Digital microfluidic isolation of single cells for -Omics. Nat Commun. 2020;11(10):5632.
   PubMedGoogle Scholar
• Akbani R, Becker KF, Carragher N, et al. Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report the RPPA (Reverse Phase Protein Array) Society. Mol Cell Proteomics. 2014;13(7):1625–1643.
   PubMed Web of Science ®Google Scholar
• Petricoin E, Wulfkuhle J, Howard M, et al. RPPA: origins, transition to a validated clinical research tool, and next generations of the technology. In: Yamada T, Nishizuka SS, Mills GB, et al., editors. Reverse Phase Protein Arrays [Internet]. Singapore: Springer Singapore; 2019 [cited 2021 Jun 20]. p. 1–19. Available from:
   Google Scholar
• Martinez-Morilla S, Villarroel-Espindola F, Wong PF, et al. Biomarker discovery in patients with immunotherapy-treated melanoma with imaging mass cytometry. Clin Cancer Res. 2021;27(7):1987–1996.
   PubMed Web of Science ®Google Scholar
• Maliga Z, Nirmal AJ, Ericson NG, et al. Micro-region transcriptomics of fixed human tissue using Pick-Seq [Internet]. Cancer Biology; 2021 [cited 2021 Jun 14]. Available from: .
   Google Scholar
• Negm OH, Muftah AA, Aleskandarany MA, et al. Clinical utility of reverse phase protein array for molecular classification of breast cancer. Breast Cancer Res Treat. 2016;155(1):25–35.
   PubMed Web of Science ®Google Scholar
• Schürch CM, Bhate SS, Barlow GL, et al. Coordinated cellular neighborhoods orchestrate antitumoral immunity at the colorectal cancer invasive front. Cell. 2020;182(1341–1359.e19):1341–1359.e19.
   PubMedGoogle Scholar
• Panda A, Betigeri A, Subramanian K, et al. Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors. JCO Precis Oncol. 2017;1–13. DOI: https://doi.org/10.1200/PO.17.00146
   Google Scholar
• Panda A, de Cubas AA, Stein M, et al. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight. 2018;3(16). DOI:https://doi.org/10.1172/jci.insight.121522.
   PubMed Web of Science ®Google Scholar
• Locy H, de Mey S, de Mey W, et al. Immunomodulation of the tumor microenvironment: Turn foe into friend. Front Immunol. 2018;9:2909.
   PubMed Web of Science ®Google Scholar
• Dickinson SE, Khawam M, Kirschnerova V, et al. Increased PD‐L1 expression in human skin acutely and chronically exposed to UV irradiation. Photochem Photobiol. 2021;97(4):778–784.
   PubMed Web of Science ®Google Scholar
• Pierobon M, Hodge KA, Baldelli E, et al. Abstract 3129: PD-L1 expression differs across cancer metastatic sites from breast tumors. Tumor Biol [Internet]. American Association for Cancer Research; 2018 [cited 2021 Aug 2]. p. 3129–3129. Available from: .
   Google Scholar
• Pierobon M, Baldelli E, Hodge KA, et al. Development of a quantitative PD-L1 assay using laser capture microdissection (LCM)-based reverse phase protein microarray (RPPA) workflow: implications for precision medicine. J Clin Oncol. 2018;36(5_suppl): 35–35. DOI:https://doi.org/10.1200/JCO.2018.36.5_suppl.35.
   Google Scholar
• Baldelli E, Calvert V, Hodge KA, et al. Abstract 5656: quantitative measurement of PDL1 expression across tumor types using laser capture microdissection and reverse phase protein microarray. Immunology [Internet]. American Association for Cancer Research; 2017 [cited 2021 Aug 2]. p. 5656–5656. Available from: .
   Google Scholar
• Hunt AL, Pierobon M, Baldelli E, et al. The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow. Clin Proteomics. 2020;17(1):9.
   PubMed Web of Science ®Google Scholar
• Balis U, Hipp J, Cheng J, et al. SIVQ-aided laser capture microdissection: a tool for high-throughput expression profiling. J Pathol Inform. 2011;2(1):19.
   PubMedGoogle Scholar
• Harbeck N. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer. Breast Edinb Scotl. 2019;48(Suppl 1):S97–S102.
   PubMedGoogle Scholar
• Bartsch R, Bergen E, Galid A. Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. Memo. 2018;11(3):199–203.
   PubMedGoogle Scholar
• Nekljudova V, Loibl S, von Minckwitz G, et al. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). Contemp Clin Trials. 2018;71:194–198.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-Positive breast cancer. N Engl J Med. 2019;380(7):617–628.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.
   PubMed Web of Science ®Google Scholar
• Ditsch N, Untch M, Kolberg-Liedtke C, et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2020. Breast Care. 2020;15(3):294–309.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet Lond Engl. 2014;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol Off J Eur Soc Med Oncol. 2013;24(9):2278–2284.
   PubMed Web of Science ®Google Scholar
• Gradishar WJ. HER2 therapy — an abundance of riches. N Engl J Med. 2012;366(2):176–178.
   PubMed Web of Science ®Google Scholar
• Hayes DF, Phimister EG. HER2 and breast cancer - a phenomenal success story. N Engl J Med. 2019;381(13):1284–1286.
   PubMed Web of Science ®Google Scholar
• Goutsouliak K, Veeraraghavan J, Sethunath V, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17(4):233–250.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Vernaci G, Guarneri V. Escalation and de-escalation in HER2 positive early breast cancer. Curr Opin Oncol. 2019;31(1):35–42.
   PubMed Web of Science ®Google Scholar
• Guarneri V, Dieci MV, Bisagni G, et al. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(6):921–926.
   PubMed Web of Science ®Google Scholar
• Akimoto E, Kadoya T, Kajitani K, et al. Role of 18 F-PET/CT in predicting prognosis of patients with breast cancer after neoadjuvant chemotherapy. Clin Breast Cancer. 2018;18(1):45–52.
   PubMed Web of Science ®Google Scholar
• van Ramshorst MS, Loo CE, Groen EJ, et al. MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2017;164(1):99–106.
   PubMed Web of Science ®Google Scholar
• Gebhart G, Gámez C, Holmes E, et al. 18 F-FDG PET/CT for early prediction of response to neoadjuvant Lapatinib, Trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med. 2013;54(11):1862–1868.
   PubMedGoogle Scholar
• Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:2768–2772.
   PubMed Web of Science ®Google Scholar
• DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(6):1152–1160.
   PubMed Web of Science ®Google Scholar
• Cicenas J, Urban P, Küng W, et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer. 2006;42(5):636–645.
   PubMed Web of Science ®Google Scholar
• Frogne T, Laenkholm A-V, Lyng MB, et al. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors. Breast Cancer Res. 2009;11(1):R11.
   PubMed Web of Science ®Google Scholar
• Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(18):3230–3239.
   PubMed Web of Science ®Google Scholar
• Hudelist G, Köstler WJ, Czerwenka K, et al. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. Int J Cancer. 2006;118(5):1126–1134.
   PubMed Web of Science ®Google Scholar
• Jameson GS, Petricoin EF, Sachdev J, et al. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat. 2014;147(3):579–588.
   PubMed Web of Science ®Google Scholar
• Sereni MI, Baldelli E, Gambara G, et al. Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers. Br J Cancer. 2017;117(4):494–502.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Matei D, Aghajanian C, et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006;24(26):4324–4332.
   PubMed Web of Science ®Google Scholar
• Lee AV, Cui X, Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7:4429s–4435s. discussion 4411s-4412s.
   PubMed Web of Science ®Google Scholar
• Ahmad DAJ, Negm OH, Alabdullah ML, et al. Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. Breast Cancer Res Treat. 2016;159(3):457–467.
   PubMed Web of Science ®Google Scholar
• Mullooly M, Conklin D, McGowan PM, et al. Neratinib to inhibit the growth of triple-negative breast cancer cells. J Clin Oncol. 2015;33(15_suppl): 1099–1099. DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.1099.
   Google Scholar
• Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.
   PubMed Web of Science ®Google Scholar
• Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 2013;3(2):224–237.
   PubMed Web of Science ®Google Scholar
• Barwinska D, Ferkowicz MJ, Cheng Y-H, et al. Application of laser microdissection to uncover regional transcriptomics in human kidney tissue. J Vis Exp. 2020;61371. DOI: https://doi.org/10.3791/61371.
   Google Scholar
• Janes KA. Single-cell states versus single-cell atlases — two classes of heterogeneity that differ in meaning and method. Curr Opin Biotechnol. 2016;39:120–125.
   PubMed Web of Science ®Google Scholar
• Janes KA, Wang -C-C, Holmberg KJ, et al. Identifying single-cell molecular programs by stochastic profiling. Nat Methods. 2010;7(4):311–317.
   PubMed Web of Science ®Google Scholar
• Bajikar SS, Fuchs C, Roller A, et al. Parameterizing cell-to-cell regulatory heterogeneities via stochastic transcriptional profiles. Proc Natl Acad Sci. 2014;111(5):E626–E635.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ferri-Borgogno S, Sheng J, et al. SIO: a spatioimageomics pipeline to identify prognostic biomarkers associated with the ovarian tumor microenvironment. Cancers (Basel). 2021;13(8):1777.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Dou M, Piehowski PD, et al. Spatially resolved proteome mapping of Laser Capture Microdissected tissue with automated sample transfer to nanodroplets. Mol Cell Proteomics. 2018;17(9):1864–1874.
   PubMed Web of Science ®Google Scholar
• Mund A, Coscia F, Hollandi R, et al. AI-driven deep visual proteomics defines cell identity and heterogeneity [Internet]. Systems Biology; 2021 [cited 2021 Jun 14]. Available from: .
   Google Scholar
• Ezzoukhry Z, Henriet E, Cordelières FP, et al. Combining laser capture microdissection and proteomics reveals an active translation machinery controlling invadosome formation. Nat Commun. 2018;9(1):2031.
   PubMedGoogle Scholar
• Dewez F, Martin-Lorenzo M, Herfs M, et al. Precise co-registration of mass spectrometry imaging, histology, and laser microdissection-based omics. Anal Bioanal Chem. 2019;411(22):5647–5653.
   PubMed Web of Science ®Google Scholar
• Davis S, Scott C, Ansorge O, et al. Development of a sensitive, scalable method for spatial, cell-type-resolved proteomics of the human brain. J Proteome Res. 2019;18(4):1787–1795.
   PubMed Web of Science ®Google Scholar
• Xu R, Tang J, Deng Q, et al. Spatial-Resolution cell type proteome profiling of cancer tissue by fully integrated proteomics technology. Anal Chem. 2018;90(9):5879–5886.
   PubMed Web of Science ®Google Scholar
• Sigdel TK, Piehowski PD, Roy S, et al. Near-Single-Cell proteomics profiling of the proximal tubular and glomerulus of the normal human kidney. Front Med. 2020;7:499.
   Web of Science ®Google Scholar
• Großerueschkamp F, Bracht T, Diehl HC, et al. Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics. Sci Rep. 2017;7(1):44829.
   PubMedGoogle Scholar
• Mezger STP, Mingels AMA, Bekers O, et al. Mass spectrometry spatial-omics on a single conductive slide. Anal Chem. 2021;93(4):2527–2533.
   PubMed Web of Science ®Google Scholar
• Risom T, Glass DR, Liu CC, et al. Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma [Internet]. Cancer Biology; 2021 [cited 2021 Jul 30]. Available from: .
   Google Scholar
• Chen J, Suo S, Tam PP, et al. Spatial transcriptomic analysis of cryosectioned tissue samples with Geo-seq. Nat Protoc. 2017;12(3):566–580.
   PubMed Web of Science ®Google Scholar
• Singh S, Wang L, Schaff DL, et al. In situ 10-cell RNA sequencing in tissue and tumor biopsy samples. Sci Rep. 2019;9(1):4836.
   PubMedGoogle Scholar
• Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20(16):1981–1989.
   PubMed Web of Science ®Google Scholar
• Sutcliffe MD, Galvao RP, Wang L, et al. Premalignant oligodendrocyte precursor cells stall in a heterogeneous state of replication stress prior to gliomagenesis. Cancer Res. 2021;81(7):1868–1882.
   PubMed Web of Science ®Google Scholar
• Narayanan M, Martins AJ, Tsang JS. Robust inference of cell-to-cell expression variations from single- and K-Cell profiling. PLOS Comput Biol. 2016;12(7):e1005016. Gottardo R, editor.
   PubMed Web of Science ®Google Scholar
• Nichterwitz S, Nijssen J, Storvall H, et al. LCM-seq reveals unique transcriptional adaptation mechanisms of resistant neurons and identifies protective pathways in spinal muscular atrophy. Genome Res. 2020;30(8):1083–1096.
   PubMed Web of Science ®Google Scholar
• Foley JW, Zhu C, Jolivet P, et al. Gene expression profiling of single cells from archival tissue with laser-capture microdissection and Smart-3SEQ. Genome Res. 2019;29(11):1816–1825.
   PubMed Web of Science ®Google Scholar
• Pereira EJ, Burns JS, Lee CY, et al. Sporadic activation of an oxidative stress–dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies. Sci Signal. 2020;13(627):eaba4200.
   PubMed Web of Science ®Google Scholar
• Singh S, Sutcliffe MD, Repich K, et al. Pan-Cancer drivers are recurrent transcriptional regulatory heterogeneities in early-stage luminal breast cancer. Cancer Res. 2021;81(7):1840–1852.
   PubMed Web of Science ®Google Scholar
• Loganathan J, Pandey R, Ambhore NS, et al. Laser-capture microdissection of murine lung for differential cellular RNA analysis. Cell Tissue Res. 2019;376(3):425–432.
   PubMed Web of Science ®Google Scholar
• Schaff DL, Singh S, Kim K-B, et al. Fragmentation of small-cell lung cancer regulatory states in heterotypic microenvironments. Cancer Res. 2021;81(7):1853–1867.
   PubMed Web of Science ®Google Scholar
• Kurth F, Wilson RE, Trüssel AJ, et al. Bridging the gap: towards microfluidic single cell analysis of in vivo stimulated cells.:3 17th International Conference on Miniaturized Systems for Chemistry and Life Sciences; 27-31 October 2013. DOI: https://doi.org/10.1002/smll.201903905
   Google Scholar
• O’Sullivan SJ, Reyes BAS, Vadigepalli R, et al. Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional profiles of single cells: a systems biology approach to opioid dependence. J Vis Exp. 2020;60612. DOI: https://doi.org/10.3791/60612
   Google Scholar
• Surrette C, Shoudy D, Corwin A, et al. Microfluidic tissue mesodissection in molecular cancer diagnostics. SLAS Technol Transl Life Sci Innov. 2017;22:425–430.
   PubMed Web of Science ®Google Scholar
• Coope RJ, Schlosser C, Corbett RD, et al. Whole‐slide laser microdissection for tumour enrichment. J Pathol. 2021;253(2):225–233.
   PubMed Web of Science ®Google Scholar
• Au Q, Fu M, Bordwell A, et al. Abstract MultiOmyx TM : a multiplexed immunofluorescent assay capable of profiling protein expression and phosphorylation, in combination with next-generation sequencing from a single FFPE tissue section. Mol Cell Biol [Internet]. American Association for Cancer Research; 2015 [cited 2021 Jul 30]. p. 2014–2014. Available from: .
   Google Scholar
• Srinidhi CL, Ciga O, Martel AL. Deep neural network models for computational histopathology: a survey. Med Image Anal. 2021;67:101813.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, et al. Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer. Clin Cancer Res. 2021; clincanres.CCR-21-0607-A.2021. DOI:https://doi.org/10.1158/1078-0432.CCR-21-0607.
   Google Scholar
• Maurer C, Holmstrom SR, He J, et al. Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes. Gut. 2019;68(6):1034–1043.
   PubMed Web of Science ®Google Scholar